NCT01719302 - Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Stage III Adult Soft Tissue Sarcoma

Interventions

DRUG

Gemcitabine

1500 mg/m\^2 given days 1 and 15 of every 28 day cycle for a total of 4 cycles

DRUG

Docetaxel

50 mg/m\^2 on days 1 and 15 of each 28 day cycle for a total of 4 cycles

DRUG

Pazopanib

Starting dose of 400 mg/day starting 72 hours after docetaxel/gemcitabine administration for 10 days (days 4-13 and 18-27) of each 28 day cycle for a total of 4 cycles. Dose will be increased by 200 mg/day for each cohort until the maximum tolerated dose is identified.

Trial Locations (1)

05401

Fletcher Allen Health Care, Burlington